Quadruple SGLT2i/GLP-1RA/ARNI/MRA Therapy for Heart Failure: Maximum Neurohormonal Blockade | Research

The takeaway

Quadruple combination of SGLT2i, GLP-1 RA, ARNI, and MRA provides comprehensive neurohormonal blockade for heart failure, with each agent targeting distinct pathways for additive cardiorenal benefit.

4 drugs, 4 pathways
Quadruple combination attacks heart failure from four different neurohormonal angles simultaneously — the most comprehensive blockade ever attempted

What the researchers found

Quadruple SGLT2i + GLP-1 RA + ARNI + MRA: comprehensive neurohormonal blockade targeting 4 distinct pathways for additive cardiorenal benefit in heart failure.

Why it matters

HF mortality remains high. Quadruple therapy attacking four neurohormonal pathways simultaneously could dramatically improve outcomes.

How the study worked

Review of quadruple combination therapy rationale, mechanisms, and evidence for heart failure.

What this study cannot tell us

Quadruple therapy evidence mostly extrapolated from individual drug trials. Safety and cost of 4-drug regimen uncertain.

How to read the evidence

Review extrapolating from individual drug trials. Combination evidence limited.

When this study was published

Published in 2025.

The bigger picture

Heart failure therapy is evolving toward comprehensive pathway blockade — similar to how cancer treatment uses combination chemotherapy.

Questions still open

Is quadruple therapy safe for all HF patients?
What is the optimal sequencing of adding each drug?
Does the cost-benefit justify quadruple therapy?

Common questions

Why four drugs for heart failure?

Each drug targets a different pathway causing heart failure. Together, they provide the most complete treatment possible — like attacking a problem from four different angles simultaneously.

Is this safe?

Individual drugs are proven safe. The combination needs more study, but early evidence and mechanistic rationale support it for appropriate patients.

Read the original research

Quadruple combination therapy with SGLT2i, GLP-1RA, ARNI and MRA in heart failure with preserved ejection fraction patients with type 2 diabetes mellitus: A prospective and observational cohort study.

Kardiologia polska, 84(1), 28-36

View on PubMed ↗Publisher’s paper ↗

Citation

Ke, Jiahan; Qiu, Xiaohan; Wang, Min; Zeng, Huasu; Wang, Changqian; Zhang, Junfeng; Chen, Kan; Gu, Jun. (2026). Quadruple combination therapy with SGLT2i, GLP-1RA, ARNI and MRA in heart failure with preserved ejection fraction patients with type 2 diabetes mellitus: A prospective and observational cohort study.. Kardiologia polska, 84(1), 28-36. https://doi.org/10.33963/v.phj.109920